<DOC>
	<DOCNO>NCT00805805</DOCNO>
	<brief_summary>The University Michigan conduct study investigate potential new treatment aim slowing/halting progression primary biliary cirrhosis . This 2 arm double blind study half patient randomly select receive placebo ( capsule active ingredient ) half receive new treatment drug , tetrathiomolybdate . Neither patient treat physician know arm patient . The length study patient 24 month drug therapy . Lab draw necessary weekly first 6 week study , follow every week 3 week , monthly remainder 2 year period . In addition , intermittent history physicals urine sample also necessary . There cost experimental treatment . All patient arm continue ursodiol receive standard care treatment</brief_summary>
	<brief_title>Study Comparing Tetrathiomolybdate v Standard Treatment Primary Biliary Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Tetrathiomolybdate</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<criteria>Generally medically healthy Age 18 older Documented primary biliary cirrhosis Alkaline phosphatase &gt; 137 Severe liver decompensation Requirement renal dialysis Pregnancy nursing Meld score &gt; 15 ( 1315 require physician 's clinical judgment ) Uncontrolled congestive heart failure Severe diabetic neuropathy Severe pulmonary disease Advanced cancer Requirement steroid therapy Uncontrolled ascites , variceal hemorrhage spontaneous bacterial peritonitis Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Copper</keyword>
	<keyword>ceruloplasmin</keyword>
	<keyword>tetrathiomolybdate</keyword>
</DOC>